Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Research and Innovation Action · Running

ARISTOTELES Applying ARtificial Intelligence to Define clinical trajectorieS for personalized predicTiOn and early deTEctiOn of comorbidiTy and muLtimorbidiTy pattErnS

Coordinator
Universita Degli Studi Di Modena E Reggio Emilia, Italy
Runs
1 November 2023 to 31 October 2028
Status
Running
EU funding
€4.1m
Total cost
€4.1m
Partners
18 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101080189

What the project is doing

In the project's own words, from its summary on CORDIS.

The ARISTOTELES project aims to build a multinational harmonized data platform to develop and implement novel artificial intelligence (AI) approaches for management of complex diseases, where progression and manifestations of comorbidities are via multiple interacting pathways. We aim to apply our novel approach to a population of great need due to atrial fibrillation (AF), but our outputs can be extended to other complex diseases with multimorbidity.

By integrating AIs into clinical practice, our platform will form a backbone for acceptable, responsible, and respectful uses of patient/participant data to develop and validate novel trustworthy AI tools for more personalized risk assessment and management. This represents a paradigm shift in AF treatment, moving from a focus on individual risk factors and selected outcomes (eg. stroke) to a holistic approach, underpinning timely diagnostic and therapeutic interventions to reduce disease progression, disability, hospitalizations and mortality, as well as improve patient adherence to lifestyle modifications, medications, and other treatment regimens.

ARISTOTELES will be delivered through 8 inter-linking work-packages (WPs): WP1 is study management/coordination. WP2 provides the ethical/legal requirements for the development of a trustworthy AI. WP3 addresses stakeholder understanding of AI, needs assessment, and engagement in all the phases of the AI development. In WP4, granular data on genotype and phenotype characteristics, are harmonized from different datasets into a common platform.

In WP5, AI algorithms/tools are developed and connected to an interactive output interface for patients and clinicians. In WP6, we test the AI tool developed in WP5 in a clinical trial simulation (in silico trial). In WP7 a multicenter randomized trial runs across multiple countries including both primary care and secondary care. WP7 and WP8 drive the clinical implementation and dissemination of results.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di Modena E Reggio EmiliaModenaItalyCoordinator
Moverim SRLBruxelles / BrusselBelgiumParticipant
Aalborg UniversitetAalborgDenmarkParticipant
Panepistimio KritisRethimnoGreeceParticipant
Idoven 1903 SLMadridSpainAssociatedpartner
Iotic Solutions SLMurciaSpainParticipant
Universidad De MurciaMurciaSpainParticipant
Gers SASBoulogne-BillancourtFranceParticipant
Datariver SRLModenaItalyAssociatedpartner
Hcf Fondazione Anmco per Il Tuo Cuore EtsFirenzeItalyParticipant
Universitetet I OsloOsloNorwayParticipant
Universidade De CoimbraCoimbraPortugalParticipant
Universitatea De Medicina Si Farmacie Carol Davila Din BucurestiBucurestiRomaniaParticipant
Aimes Management Services LimitedLiverpoolUnited KingdomAssociatedpartner
Liverpool John Moores UniversityLiverpoolUnited KingdomAssociatedpartner
The University of LiverpoolLiverpoolUnited KingdomAssociatedpartner
The University of ManchesterManchesterUnited KingdomAssociatedpartner
University College LondonLondonUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI